Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.

Sheng-Teng Huang26 enrolled

Overview

These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.

The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to present challenges despite widespread vaccination efforts, with breakthrough infections remaining a concern. This has led to increased interest in exploring alternative preventive measures, including dietary and natural product-based interventions. Previous studies have demonstrated the potential of herbal medicines in inhibiting viral infections and as therapies for COVID-19. Additionally, research has identified various herbal medicines with inhibitory properties against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, highlighting their potential in combating the virus. Here Researchers found that novel herbal medicine formula Kang Guan Recipe (KGR) is a potent inhibitor against SARS-CoV-2 viral infection. Researchers demonstrated that KGR showed inhibitory activity against variants of concern (VOCs) of SARS-CoV-2 infection. Moreover, they also found that KGR can block the interaction of viral Spike and human angiotensin-converting enzyme 2 (ACE2). Furthermore, Researchers assessed the inhibitory effect of KGR on SARS-CoV-2 viral entry in vivo and observed that serum samples from healthy human subjects exhibited suppressive activity against various SARS-CoV-2 variants after consuming KGR. These studies offer valuable insights into the potential development of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Coronavirus Disease 2019 Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Interventions

Kang Guan Recipe (Treat)COMBINATION_PRODUCT

Accurately weigh the Chinese medicinal herbs in the formula by weight, conduct the origin identification of the medicinal materials, and follow the scientific traditional Chinese medicine preparation process. After extraction, concentration, and granulation, package them in aluminum foil, with each package containing 6 grams of concentrated powder.

Kang Guan Recipe (Placebo)COMBINATION_PRODUCT

Use 3% Kang Guan Recipe concentrated powder, mix evenly with starch, and package in aluminum foil, with each package containing 6 grams of concentrated powder.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy participants aged 20-60 with a body weight of over 50 kilograms. * Individuals who have never been diagnosed with COVID-19 or have recovered from COVID-19 for more than three months. * No consumption of any traditional Chinese medicine or food containing Chinese medicine within the preceding 36 hours before the experiment. * Vaccinated individuals who received their vaccine more than three months ago. * Willingness to undergo venous blood tests (approximately 10 cc of blood to be drawn three times). Exclusion Criteria: * History of major internal medical conditions, including diabetes, hypertension, chronic obstructive pulmonary disease (COPD), asthma, abnormal liver function (AST levels exceeding 5 times the normal value), renal dysfunction (eGFR \<60), cancer, etc. * Brain disorders such as trauma, stroke, tumors, epilepsy, or dementia. * Mental health disorders such as depression, anorexia nervosa, or schizophrenia. * Pregnant or lactating women. If there is suspicion of pregnancy, a commercial urine pregnancy test will be conducted. * Smokers, alcoholics, or betel nut addicts. * Inability to comply with the trial procedures. * Inability to sign the informed consent form. * Within three months of a confirmed COVID-19 diagnosis. * Within three months of receiving a vaccine shot.

Locations (1)

China Medical University Hospital

Taichung, North District, Taiwan

Outcomes

Primary Outcomes

Serum Infection rate of pseudocells

Collected Blood, centrifuge to obtain serum samples. Each serum sample were diluted and premixed with wild-type or different variants of SARS-CoV-2 spike Vpps for one hours before incubation with 293T-ACE2 cells. After 24 hours of infection, the infection efficiency rate was measured according to luciferase activities.

Time frame: Before taking, 2 hours after taking, and 2 hours after taking 24 hours later.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.